Patients with the following symptoms and signs require immmediate assessment for the initiation of ACS protocol:
• Chest pain or severe epigastric pain, non-traumatic in origin, with component typical of myocardial ischema or MI: Central/substernal compression or crushing chest pain pressure, tightness, heaviness, cramping, burning, aching sensation.
• Unexplained indigestion, belching, epigastric pain.
• Radiating pain in neck, jaw, shoulders, back, 1 or both arms.
• Associated dyspnea.
• Associated nausea and/or vomitting.
• Associated diaphoresis.
Statement 2: Electrocardiogram
It is STRONGLY RECOMMENDED that a 12 lead ECG be obtained immediately within 10 minutes of ER presentation in patients with ongoing chest discomfort.
Statement 3: Treadmill Exercise Test
It is NOT RECOMMENDED to perform stress test within 48 hours of the last chest pain.
Statement 4: Biomarkers of Cardiac Injury
It is STRONGLY RECOMMENDED that troponin be measured in all patients with chest discomfort consistent with ACS. In patients with negative cardiac markers within 6 hours of the onset of pain, another sample should be drawn in the time frame 8-12 after symptom onset.
Statement 5: Other Biomarkers
It is NOT RECOMMENDED to request for Total CK (without MB), AST, SGOT, beta hydroxybutyric dehydrogenase, and/or lactate dehydrogenase (LDH) as markers for the detection of cardiac injury.
Statement 6: Risk Stratification
It IS RECOMMENDED for patients who present with chest discomfort or other ischemic symptom to undergo early risk stratification for risk of cardiovascular events (e.g., death or MI) based on an integration of the patient's history physical examination, ECG findings and result of cardiac biomarkers.
Statement 7: General Recommendations on Initial Management
It IS RECOMMENDED that the following management strategies should be instituted:
1. Bed rest with continuous ECG monitoring for ischemic and arrythmia detection in patients with ongoing rest pain. 2. Supplemental oxygen should be administered to patients with UA/NSTEMI for patients with cyanosis of respiratory distress; finger pulse oximetry or arterial blood gas determination to confirm adequate arterial oxygen saturation (SaO2 greater than 90%) and continued need for supplemental oxygen in the presence of hypoxemia.
Statement 8: Nitrates
It IS RECOMMENDED that nitrates (sublingual tablet or spray), followed by intravenous administration, be administered for the immediate relief of ischemic and associated symptoms.
Statement 9: Beta blockers
It IS RECOMMENDED that beta-blocker by oral or IV route be administered if there is ongoing chest pain in the absence of contraindications.
Statement 10: Calcium channel blockers
It MAY BE RECOMMENDED to use oral long-acting calcium antagonists for recurrent ischemia in the absence of contraindication and when beta-blockers and nitrates are maximally used.
Statement 11: Angiotensin Converting Enzyme Inhibitor (ACE-I) or Angiotensin Receptor Blockers (ARB)
An ACE-I/ARB IS RECOMMENDED when hypertension persists despite treatment with nitroglycerin (NTG) and a beta-blocker in patients with LV systolic dysfunction or congestive heart failure (CHF), high risk chronic CAD, in post ACS (with or without) diabetes, and in chronic kidney disease (CKD) unless contraindicated.
Statement 12: Morphine sulfate
It IS RECOMMENDED that morphine sulfate be administered intravenously when symptoms are not immediately relieved with NTG or when acute pulmonary congestion and/or severe agitation are present.
Statement 13: Aspirin
It is STRONGLY RECOMMENDED that aspirin at initial dose of 160-325 mg non-enteric formulation, followed by 80-160 mg daily, be administered as soon as possible after presentation and continued indefinitely.
Statement 14: ADP receptor antagonists (Clopidogrel, Ticlodipine)
It IS STRONGLY RECOMMENDED to start clopidogrel for: 1. Patients in whom an early non-interventional approach is planned in addition to ASA as soon as possible in admission and administered for at least a month. 2. Patients who are unable to take ASA because of hypersensitivity or major gastrointestinal intolerance. 3. Patients in whom a PCI is planned and should be continued for at least 12 months in patients who are not at high risk for bleeding.
It IS STRONGLY RECOMMENDED to discontinue clopidogrel for 5 to 7 days in patients whom elective CABG is planned.
Statement 15: Anticoagulants (Heparins)
It IS STRONGLY RECOMMENDED that anticoagulation with subcutaneous enoxaparine or intravenous unfractioned heparin (UFH) should be added to anti-platelet therapy with ASA and/or clopidogrel.
Statement 16: Glycoprotein IIb IIIa Inhibitors
It IS RECOMMENDED to use glycoprotein IIb IIIa inhibitors (tirofiban) in addition to ASA and LMWH or UFH, to patients with continuing ischemia, an elevated troponin or with other high risk features in whom an invasive management strategy is not planned; or in patients undergoing PCI with or without clopidogrel administration.
Statement 17: Factor X Inhibitor
It IS RECOMMENDED to use fondaparinux, in lieu of enoxaparine, at a dose of 2.5 mg SC once daily in whom a conservative strategy is selected and who have an increased risk of bleeding.
Statemetent 18: Fibrinolytic Therapy
It IS NOT RECOMMENDED to use intravenous fibrinolytic therapy in patients with UA or in patients without acute ST-segment elevation, a true posterior MI, or a presumed MI, or a presumed new left bundle-branch block (LBBB).
Statement 19: Early Conservative versus Invasive Strategies
It IS RECOMMENDED that an early invasive strategy (as early as possible up to 72 hours) followed by revascularization (PCI or CABG) with any of the following high-risk indicators: a. Recurrent angina/ischemia at rest or with low-level activities despite intensive anti-ischemic therapy. b. Elevated cardiac biomarkers (TnT or TnI). c. New or presumably new ST-segment depression. d. Signs and symptoms of Heart Failure (HF) or new or worsening mitral regurgitation. e. High-risk findings from noninvasive testing f. Hemodynamic instability g. Sustained ventricular tachycardia. h. PCI within 6 months. i. Prior CABG. j. High-risk score (e.g., TIMI, GRACE). k. Reduced LV systolic function (LVEF less than 40%).
Statement 20: Coronary angiography
It IS NOT RECOMMENDED in patients with extensive co-morbidities (e.g., liver or pulmonary failure, cancer), in whom the risks of revascularization are not likely to outweigh the benefits or in patients with acute chest pain and a low likelihood of ACS or in patients who will not consent to revascilarization regardless of the findings. 
II. DIAGNOSIS AND RISK ASSESSMENT
Patients with a high likelihood of ischemia due to CAD are at greater risk of an untoward cardiac event than are patients with a lower likelihood of CAD. Therefore, an assessment of the likelihood of CAD is the starting point for the determination of prognosis in patients who present with symptoms suggestive of an ACS. • Associated dyspnea.
Statement 1: Diagnosis and Risk Assessment
The clinical presentation of patients with unstable angina and non ST elevation MI present itself in variety of symptoms. However, the frequent and typical manifestations would be the following:
• Prolonged (>20 minutes) anginal pain at rest • New onset severe angina • Crescendo/accelerated angina • Post MI angina
Statement 2: Electrocardiogram

It Is sTRONGLY RECOMMENDED that a 12 lead ECG be obtained immediately within 10 minutes of ER presentation in patients with ongoing chest discomfort.
If the initial ACG is not diagnostic, but the patient remains symptomatic and there is high clinical suspicions for ACS, serial ECGs, initially at 15-30 minute intervals, should be performed to detect the potential for development of ST segment elevation or depression.
The ECG is critical not only to add support to the clinical suspicion of CAD but also to provide prognostic information that is based on the pattern and magnitude of the abnormalities. Importantly, transient ST-segment changes (greater than or equal to 0.05 mV) that develop during a symptomatic episode at rest and that resolve when the patient becomes asymptomatic strongly suggest acute ischemia and a very high likelihood of underlying severe CAD.
Patients who present with ST-segment depression are initially considered to have either UA or NSTEMI; the distinction between the 2 diagnosis is based ultimately on the detection in the blood of markers of myocardial necrosis.
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Statement 3: Treadmill Exercise Test
In patients who continue to have typical chest pain, stress test should not be performed. However, stress test has been used as a predictive tool of prognosis in patients with non-diagnostic ECG provided there is no chest pain, no signs of heart failure and normal cardiac markers on repeat examination. cTNT or cTNI are the preferred markers of myocardial injury because they are mote sensitive than the traditional cardiac enzymes such as creatinine kinase (CK) or its isoenzyme MB (CKMB). Additionally, troponins are the best biomarker to predict short-term (<30 days) outcome with respect to MI and death. 4, 5, 6 In patients with AMI, an initial rise in troponins in peripheral blood occurs after 3-4 hours. Troponin levels may persist for up to 2 weeks. In NSTEMI, minor elevation of troponins may be measurable only over 48-72 hours. The high sensitivity of troponin tests allows the detection of myocardial damage undetected by CKMB in up to one third of patients. With currently available assays, cTnI and cTnT are of equal sensitivity and specificity in the detection of cardiac damage. 7 The choice should be made on the basis of cost and the availability of instrumentation at the institution.
A single negative test for troponins on arrival of the patient in the hospital is not sufficient for ruling out an ACS. Repeated blood sampling and measurements are required 6-12 hours after admission and after any further episodes of severe chest pains.
Statement 5: Other Biomarkers
It is NOT RECOMMENDED to request for Total CK (without MB), AST, SGOT, beta hydroxybutyric dehydrogenase, and/or lactate dehydrogenase (LDH) as markers for the detection of cardiac injury.
Statement 6: Risk Stratification
It is RECOMMENDED for patients who present with chest discomfort or other ischemic symptom to undergo early risk stratification for risk of cardiovascular events (e.g., death or MI) based on an integration of the patient's history physical examination, ECG findings and result of cardiac biomarkers.
Early risk stratification is useful in (1) selection of the site of care (coronary artery unit, monitored step-down unit, or out-patient setting) and (2) selection of therapy, including platelet glycoprotein (GP) IIb-IIIa inhibitors and invasive management strategy. A number of risk assessment tools have been developed in assessing risk of death and ischemic events; these are the Thrombolysis in Myocardial Infarction (TIMI) risk score 8 , Platelet Glycoprotein IIb-IIIa in Unstable Angina (PURSUIT) risk model 9 , and the Global Registry of Acute Coronary Events (GRACE) risk model (See Figure 1) . 10, 11 See Table 1 for the comparison of the 3 risk models.
The TIMI risk score is determined by the sum of the presence of 7 variables at admission (Age 65 years or older, at least 3 risk factors for CAD, prior coronary stenosis of 50% or more, ST-segment deviation on ECG presentation, at least 2 anginal events in prior 24 hours, use of aspirin in prior 7 days, elevated serum cardiac biomarkers); 1 point is given for each of these variables. (See Table 2 Learn to access drug info on your cellphone. Send PPD to 2600 for Globe/Smart/Sun users.
In the PURSUIT risk model, critical clinical features associated with an increased 30-day incidence of death and the composite of death or myocardial (re)infarction were (inorder of strength) age, heart rate, systolic blood pressure, ST-segment depression, signs of heart failure (HF), and cardiac enzymes. In the GRACE risk model, the 8 variables used are older age, Killip class, systolic blood pressure, ST-segment deviation, cardiac arrest during presentation, serum creatinine level, positive initial cardiac markers, and heart rate. The sum of scores is applied to a reference nomogram to determine the corresponding all-cause mortality from hospital discharge to 6 months (See Figure 1) . Any of these risk scores or models can be used to assess risk of death and myocardial infarction in patients with NSTEMI and UA.
III. HOSPITAL CARE Statement 7: General Recommendations on Initial Management
It IS RECOMMENDED that the following management strategies should be instituted: 1. Bed rest with continuous ECG monitoring for ischemic and arrythimia detection in patients with ongoing rest pain. 2. Supplemental oxygen should be administered to patients with UA/NSTEMI for patients with cyanosis of respiratory distress; finger pulse oximetry or arterial blood gas determination to confirm adequate arterial oxygen saturation (SaO2 greater than 90%) and continued need for supplemental oxygen in the presence of hypoxemia.
Statement 8: Nitrates
It IS RECOMMENDED nitrates (sublingual tablet or spray), followed by intravenous administration, be administered for the immediate relief of ischemic and associated symptoms.
For initial management of anginal pains, three 0.4 mg sublingual NTG tablets or spray taken 5 min apart can be administered. If symptoms are not relieved, intravenous NTG may be initiated at a rate of 10 mcg/min through continuous infusion with nonabsorbing tubing and increased by 10 mcg per min every 3 to 5 min until some symptom or blood pressure response is noted. Caution should be used when systolic blood pressure falls to less than 110 mm Hg in previously normotensive patients or greater than 25% below the starting mean arterial blood pressure if hypertension was present. Although recommendations for a maximum dose are not available, a ceiling of 200 mcg per min is commonly used. When patients have been free of pain and other manifestations of ischemia for 12 to 24 hours, an attempt should be made to reduce the dose of intravenous NTG and to switch to oral or topical nitrates (See Table 3 The administration of the following treatment strategies can be done but with caution: 1. Extended-release form of non-dihydropyridine calcium antagonists instead of a beta-blocker. 2. Immediate-release dihydropyridine calcium antagonists in the presence of a beta-blocker.
However, it is not recommended to administer immediate-release dihydropyridine calcium antagonists in the absence of a beta-blocker.
Statement 11: Angiotensin Converting Enzyme Inhibitor (ACE-I) or Angiotensin Receptor Blockers (ARB)
An
ACE-i/ARB is RECOMMENDED when hypertension persists despite treatment with nitroglycerin (NTG) and a beta-blocker in patients with LV systolic dysfunction or congestive heart failure (CHF), high risk chronic CAD, in post ACS (with or without) diabetes, and in chronic kidney disease (CKD) unless contraindicated.
ACE-Is have been shown to reduce mortality rate in patients with AMI or who recently had an MI and have LV systolic dysfunction [18] [19] [20] [21] , in diabetic patients with LV dysfunction 22 , and in a broad spectrum of patients with high-risk chronic CAD, including patients with normal LV function.
An ACE-I is recommended for all post-ACS patients. ARBs should also be considered in patients who are
Statement 9: Beta-blockers
It is RECOMMENDED that beta-blocker by oral or IV route be administered if there is ongoing chest pain in the absence of contraindications.
Beta-blockers competitively block the effects of catecholamines on cell membrane beta-receptors. Beta-blockers should be started early in the absence of contraindications. These agents should be administered IV (the only locally available IV beta blocker is esmolol) followed by oral administration in high-risk patients as well as in patients with ongoing rest pain or orally for intermediate and low-risk patients. (see Table 4 on different beta blocker drugs) Beta blockers are contraindicated in the setting of continuing or frequently recurring ischemia, a non-dihydropyridine calcium antagonist (e.g., verapamil or ditiazem) may be administered as initial therapy in the absence of severe LV dysfunction or other contraindications.
Statement 10: Calcium channel blockers
It MAY BE RECOMMENDED to use oral long-acting calcium antagonists for recurrent ischemia in the absence of contraindication and when beta-blockers and nitrates are maximally used.
Definitive evidence for benefit with all calcium antagonists in UA is predominantly limited to symptom control. Rapid release, short-acting dihydropyridines (e.g., nifepidine) must be avoided in the absence of adequate concurrent beta-blockade in ACS because controlled trials suggest increased adverse outcomes. 13, 14, 15 Verapamil and diltiazem should be avoided in patients with pulmonary edema or evidence of severe LV dysfunction. 16 Amlodipine and felodipine, however, appear to be well tolerated by patients with chronic LV dysfunction. 17 (See Table 5 intolerant to ACE-I and/or who have heart failure or MI with LVEF<40%.
Statement 12: Morphine sulfate
It is RECOMMENDED that morphine sulfate be administered intravenously when symptoms are not immediately relieved with NTG or when acute pulmonary congestion and/or severe agitation are present.
Morphine sulfate 1 to 5 mg intravenously (IV) is recommended for patients whose symptoms are not relieved after three serial sublingual NTG tablets or whose symptoms recur despite adequate anti-ischemic therapy. Unless contraindicated by hypotension or intolerance, morphine may be administered along intravenous NTG, with careful blood pressure monitoring, and may be repeated every 5 to 30 min as needed to relieve symptoms and maintain patient comfort. Naloxone (0.4 to 2.0 mg IV) may be administered for morphine overdose with respiratory and/or circulatory depression. Meperidine hydrochloride can be substituted in patients who are allergic to morphine.
IV. ANTI-PLATELET AND ANTI-THROMBOTIC THERAPY Statement 13: Aspirin
It is sTRONGLY RECOMMENDED that aspirin at initial dose of 160-325 mg non-enteric formulation, followed by 80-160 mg daily, be administered as soon as possible after presentation and continued indefinitely.
The administration of aspirin has the strongest evidence of clinical benefit in all spectrum of ACS.
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Statement 14: ADP receptor antagonists (Clopidogrel, Ticlodipine)
The trial, Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) also provides strong evidence for the addition of clopidogrel to ASA on admission in the management of patients with UA and NSTEMI. The optimal duration of therapy with clopidogrel has not been determined, but the favorable results in CURE were observed over a period averaging 9 months. [25] [26] (See Table 6 or listing and dosages of different anti-thrombotic and anticoagulant drugs)
It IS STRONGLY RECOMMENDED to discontinue clopidogrel for 5 to 7 days in patients whom elective CABG is planned. Table 6 . Anti-thrombotic Therapy Oral anti-platelet therapy
Aspirin
Initial dose of 160-325 mg non-enteric formulation followed by 80-160 mg/d of an enteric or a non-enteric formulation Clopidogrel 75 mg/d, a loading dose of 4-8 tablets (300-600 mg) can be used when rapid onset of action is required Ticlodipine 250 mg twice daily, a loading dose of 500 mg can be used when rapid onset of inhibition is required, monitoring of platelet and while cell counts during treatment is required Heparins Dalteparin 120 IU/kg subcutaneously every 12 hours (maximum 10,000 IU twice daily) Enoxaparin 1 mg/kg subcutaneously every 12 hours, the first dose may be preceeded by a 30 mg IV bolus Nadroparin 86 IU/kg every 12 hours Unfractioned Bolus 60-70 U/kg (maximum 5000 U) IV followed by infusiom of 12-15 U/kg/k Heparin (UFH) (maximum 1000 U/hour) titrated to aPTT 1.5-2.5 times control Five trials were conducted using GPIIbIIA inhibitors in UA/NSTEMI. In PRISM and PRISM PLUS, tirofiban appears to be beneficial in high risk patients whether they underwent PCI or not. However, no benefit is observed in low risk patients. In PURSUIT trial, eptifibatide also showed benefit whether they are treated medically or with PCI. However, in GUSTO IV, Abciximab showed no advantage over placebo in medically treated patients where PCI is not planned.
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Statement 17: Factor X Inhibitor
It is RECOMMENDED to use fondaparinux, in lieu of enoxaparine, at a dose of 2.5 mg SC once daily in whom a conservative strategy is selected and who have an increased risk of bleeding.
The only selective factor-Xa inhibitor locally available for clinical use is fondaparinux. This is a synthetic pentasaccharide modeled after the anti-thrombin-binding sequence of UFH. It exerts a selective anti-thrombin-mediated inhibition of factor-Xa. Several advantages have been cited for its clinical uses over heparins. It does not induce the formation of heparin-PF4 complexes, hence heparin induced thrombocytopenia (HIT) is unlikely to occur with fondaparinux, therefore, monitoring of platelet count is not necessary. Additionally, the use of Fondaparinux has no significant influence on the usual variables that monitor anticoagulant activity, such as aPTT, activated clotting time (ACT), pro-thrombin (PT), and thrombin times (TT). This drug is eliminated mainly by the renal route and should not be given if CrCl is lower than 30 mL/min. However, this anticoagulant has propensity for increased rate of catheter-associated thrombosis.
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Statemetent 18: Fibrinolytic Therapy
The failure of IV thrombolytic therapy to improve clinical outcomes in the absence of AMI was clearly demonstrated in the TIMI IIb, ISIS 2, GISSI 1 trials. Two different treatment strategies, termed "early conservative" and "early invasive" have evolved for patients with UA/NSTEMI. In the early conservative strategy, coronary angiography is reserved for patients with evidence of recurrent ischemia (angina at rest or with minimal activity or dynamic ST-T segment changes or a strongly + stress tests despite vigorous medical therapy).In the early invasive strategy, patients without clinically obvious contraindications to coronary revascularization are routinely recommended for coronary angiography and revascularization if possible within o after presentation to the ED.
TIMI-IIIB was the first trial to compare strategies of routine catheterization and revascularization in addition to medical therapy and selective use of aggressive treatment. 42 The FRISC II and TACTICS trials [43] [44] result supports the use of catheterization and revascularization for selected patients with an acute coronary syndrome. The greater benefits derived from percutaneous coronary intervention (PCI) in the TACTICS and FRISC trials can be explained in part by the use of stents and GP-receptor blockers and lower peri-procedural complications.
A conservative strategy may be instituted for patients with low-risk score (e.g., TIMI, GRACE) or according to patient or physician preference in absence of high-risk features. 
Statement 20: Coronary angiography
